Outcome of Primary Tumor in Patients With Synchronous Stage IV Colorectal Cancer Receiving Combination Chemotherapy Without Surgery As Initial Treatment.

Slides:



Advertisements
Similar presentations
Diagnosis.
Advertisements

Pathologic Response to Preoperative Chemotherapy in Colorectal Liver Metastases: Fibrosis, not Necrosis, Predicts Outcome Ann Surg Oncol (2012) 19:2797–2804.
Adjuvant chemotherapy in resectable liver-limited metastasis colorectal cancer 指導VS: 鄧豪偉 財團法人台灣癌症臨床研究發展基金會.
T Staging: Rectal cancer T1 invades submucosa T2 invades muscularis propria T3 invades subserosa or perirectal tissues T4 invades peritoneum, organs or.
Neoadjuvant Chemotherapy in Malignant Peripheral Nerve Sheath Tumors Elizabeth Shurell, M.D., M.Phil. UCLA General Surgery Resident Research Fellow, Division.
Impact of the Type and Modalities of Preoperative Chemotherapy on the Outcome of Liver Resection for Colorectal Metastases R. Adam, E. Barroso, C. Laurent,
NSABP PROTOCOL C-10: RESULTS A Phase II Trial of 5-Fluorouracil, Leucovorin and Oxaliplatin (mFOLFOX6) Plus Bevacizumab for Patients with Unresectable.
Colon Cancer Basic Science 9/21/05. Colon and rectal neoplasms are characterized by: Consist of the third most common site of new cancer cases and deaths.
Abstract Neoadjuvant Chemotherapy First, Followed by Chemoradiation and Then Surgery, in the Management of Locally Advanced Rectal Cancer A. Cercek, K.
Alexander Stein University Cancer Center Hamburg, Germany
Management of Colorectal Liver Metastasis
Defining the Colorectal Surgeons role in patients with colorectal cancer and limited metastatic disease Jose G. Guillem, MD, MPH Department of Surgery.
Colorectal cancer Khayal AlKhayal MD,FRCSC
Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.
Bowel Cancer Alex Hill. Why screen for bowel cancer?  Bowel cancer causes deaths per yr  It may be detected at asymptomatic stage by simple, safe.
Colorectal Cancer Center Jena Introduction In Germany, there are currently approximately newly diagnosed patients with colorectal carcinoma.
Vascular issues associated with bevacizumab Stuart M. Lichtman, MD, FACP 65+ Clinical Geriatric Program Associate Attending Memorial Sloan-Kettering Cancer.
Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single agent (s/a) BEV as maintenance therapy in.
Colon Cancer First Page.
Resection For Lung Metastases M62 Coloproctology Course.
Treatment options depend on the following: – The stage of the cancer – Whether the cancer has recurred – The patient’s general health.
Treatment strategies for colon cancer at TNM stage IV Gunnar Arbman Department of Surgery Norrköping, Sweden Bergen June 2011.
COLON CANCER A MAJOR ISSUE IN ALASKA. A common malignancy 200,000 cases in the U. S. in ,000 cases in the U. S. in 2008 Greater than 50 new cases.
Is surgical resection of an asymptomatic primary colorectal tumor beneficial for patients with incurable Stage IV disease? A Phase II Trial of 5-Fluorouracil,
Potentially curative re-resection of recurrent CRC  Suture line recurrences  Isolated liver metastases  Isolated pulmonary metastases.
The Colorectal Cancer Center Jena Gharbi A, Settmacher U. Department of General, Visceral and Vascular Surgery, Friedrich-Schiller-University Jena
SYNCHRONOUS COLORECTAL AND LIVER RESECTION J Peter A Lodge MD FRCS HPB and Transplant Unit St James’s University Hospital Leeds LS9 7TF 2006 Association.
Targeting VEGF for the Treatment of Colorectal Cancer Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA.
Treatment Regimens of HER2+ Adjuvant Patients (Actuals) Source: Genentech ASCO 2005 (data release) Nov 2006 (Approval)
The treatment of metastatic squamous cell carcinoma (SCCA) of the anal canal: A single institution experience P. Pathak, B. King, A. Ohinata, P. Das, C.H.
Clara Natoli, MD Professor of Medical Oncology University G. D ' Annunzio Chieti - Pescara Clara Natoli, MD Professor of Medical Oncology University G.
T Andre, E Quinaux, C Louvet, E Gamelin, O Bouche, E Achille, P Piedbois, N Tubiana-Mathieu, M Buyse and A de Gramont. Updated results at 6 year of the.
Prognosis of colon cancer compared with rectal cancer. Where lies the difference? Bjørn S. Nedrebø Stavanger University Hospital.
T Staging: Rectal cancer T1 invades submucosa T2 invades muscularis propria T3 invades subserosa or perirectal tissues T4 invades peritoneum, organs or.
MABEL – a large multinational study of cetuximab plus irinotecan in metastatic colorectal cancer progressing on irinotecan H Wilke, R Glynne-Jones, J Thaler,
Management of Recurrent and Advanced Tumours: When are Tumours Resectable, and Multidisciplinary Management Dr. Andrew McFadden Surgical Oncology.
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of colorectal cancer: case report and literature review Alexandra.
Management of the primary in Stage IV colorectal cancer Erin Kennedy, MD, PhD, FRCSC Colorectal Surgery Mount Sinai Hospital University of Toronto.
Cmab might have therapeutic benefit in Japanese patients with KRAS p.G13D mutant colorectal cancer. Limitations of this study are its retrospective design.
EORTC Tumor response to pre-operative chemotherapy (CT) with FOLFOX-4 for resectable colorectal cancer liver metastases (LM) Interim results of the EORTC.
Phase II trial of chemotherapy with high-dose FOLFIRI plus bevacizumab in the front-line treatment of patients with metastatic colorectal cancer (mCRC)
Synchronous Metastasis on Staging/Surveillance CT chest abdomen & Pelvis + CEA + MRI Liver /PET-CT Synchronous Metastasis on Staging/Surveillance CT chest.
The impact of smoking on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB Nadine A. Jackson, Charles S.
Definition Signs & symptoms Treatment Root of the disease.
Patterns of Care in Medical Oncology Treatment of Metastatic Colon Cancer.
1 A Randomized, Multi-Center Phase III Trial of Irinotecan in Combination with Three Different Methods of Administration of Fluoropyrimidine with Celecoxib.
Interventions for Clients with Colorectal Cancer.
Surgery of colorectal metastasis in the Optimox 1 study. A GERCOR Study. N. Perez-Staub, G. Lledo, F. Paye, B. Gayet, M. Flesch, A. Cervantes, A. Figer,
LCC COL-1 See Pathologic Stage, Adjuvant Therapy, and Surveillance (LCC COL-3) Φ Φ Φ π π π Colon Cancer.
Complete pathologic responses in the primary of rectal or colon cancer treated with FOLFOX without radiation A. Cercek, M. R. Weiser, K. A. Goodman, D.
Short-term outcome of neo-adjuvant chemotherapy
SURGICAL TREATMENT OF LIVER METASTASES FROM COLORECTAL CANCER
Results of Definitive Radiotherapy in Anal Canal Carcinoma
Prognosis of younger patients in non-small cell lung cancer
The presence of lung metastases does not influence survival in liver metastatic colorectal cancer Jennie Engstrand1, Henrik Nilsson1, Cecilia Strömberg2,
Systemic treatment for colorectal cancer
A Paradigm Shift From One-Size-Fits-All to Tailor-Made Therapy for Metastatic Colorectal Cancer.
Improved survival outcomes after resection of ductal adenocarcinoma in the body and tail of the pancreas: A single center 10 years’ experience Seong.
Mahmood rasheed Hematology/oncology fellow VCU Massey cancer center
تهیه کننده: استاد مربوطه: بهار 1392
Mark W. Onaitis, MD, Rebecca P. Petersen, MD, John C
First efficacy and safety results from XELOX-1/NO16966, a randomised 2x2 factorial phase III trial of XELOX vs FOLFOX4 + bevacizumab or placebo in first-line.
Neoadjuvant Adjuvant Curative Palliative
The role of simultaneous resection of synchronous liver metastasis and primary colorectal cancer Samuel Lo Department of Surgery.
Published online September 20, 2017 by JAMA Surgery
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials E Mitry, A Fields,
Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) +/- cetuximab for patients with untreated metastatic adenocarcinoma of the.
Surgical resection of metachronous liver metastases
Presentation transcript:

Outcome of Primary Tumor in Patients With Synchronous Stage IV Colorectal Cancer Receiving Combination Chemotherapy Without Surgery As Initial Treatment George A. Poultsides, 1 Elliot L. Servais, 1 Leonard B. Saltz, 2 Sujata Patil, 3 Nancy E. Kemeny, 2 Jose G. Guillem, 1 Martin Weiser, 1 Larissa K.F. Temple, 1 W. Douglas Wong 1, Philip B. Paty 1 Departments of Surgery, 1 Medicine, 2 Epidemiology and Biostatistics, 3 Memorial Sloan-Kettering Cancer Center, New York, NY

Background In the absence of symptoms (bleeding, perforation, obstruction) or resectable metastatic disease, primary tumor resection in patients who present with synchronous metastatic colorectal cancer (CRC) is of uncertain benefit. With recent advances in systemic chemotherapy and improvement in survival of stage IV CRC patients, the risks and benefits of a deferred surgical strategy have not been completely evaluated.

Purpose To describe the frequency of primary tumor-related complications, which required operative or non-operative intervention, in patients who presented with synchronous stage IV CRC and who received up-front modern, triple- drug, oxaliplatin or irinotecan-based combination chemotherapy with or without bevacizumab, and no surgery as initial treatment.

Methods Inclusion Criteria: Patients who presented with synchronous, stage IV CRC and intact primary tumor January 1, 2000 and December 31, 2006 Asymptomatic with regard to their primary tumor (no major bleeding, perforation, impending obstruction) No previous primary tumor–directed surgery, radiotherapy, endoscopic stenting or ablation Up-front, first-line chemotherapy  Bolus fluorouracil, leucovorin, and irinotecan OR  Infusional fluorouracil, leucovorin, and oxaliplatin OR  Infusional fluorouracil, leucovorin, and irinotecan  With or without bevacizumab

Results Characteristics of 233 patients identified: Primary tumor location Right colon37% Left colon29% Rectum34% Site of metastatic disease at presentation Liver95% Retroperitoneal lymph nodes39% Lung30% Peritoneum9% Skeleton2% Brain0.4% Metastatic disease involved 1 site in 40%, 2 sites in 45%, and 3 or more sites in 14% of patients

Results

The need for emergent intervention did not correlate with overall survival when included as a time-varying covariate in a Cox regression model (p=0.81). The risk of emergent intervention was not associated with age (p=0.10), primary tumor anatomic location (p=0.19), number of metastatic sites (p=0.20), use of bevacizumab (p>0.99), CEA (p=0.18), albumin (p>0.99), LDH (p=0.80), or alkaline phosphatase level (p=0.33)

Conclusion Of 233 patients with confirmed intact primary tumor who received modern, triple-drug, combination chemotherapy for synchronous stage IV colorectal cancer at MSKCC, 93% never required surgery to palliate primary tumor-related complications. The overall peri-operative mortality of 0.8% for this population compares very favorably with what would have been expected, based on historical comparators, had all patients undergone initial palliative resection of the primary. These data strongly support the appropriateness of non- operative management as initial treatment for patients with intact primary CRC and synchronous metastases in the absence of overt obstruction or severe acute bleeding. Such patients should not undergo resection of the primary tumor prior to initiation of chemotherapy.